Company news
Allergy Therapeutics plc news in 2024
Allergy Therapeutics plc's news releases, calls and decks from 2024, newest first.
Exercise of Options and Total Voting Rights
December 19, 2024
Block Listing Interim Review
December 17, 2024
Positive Interim Data from PROTECT Trial
December 4, 2024
First Patient Dosed in G308 Paediatric Trial
November 27, 2024
Submission of MAA for Grass MATA MPL
November 25, 2024
Allergy Therapeutics plc - Notice of 2024 Annual General Meeting
November 22, 2024
Notice of 2024 Annual General Meeting
November 21, 2024
Audited Preliminary Results 2024
November 6, 2024
Commencement of Phase III Paediatric Trial
October 21, 2024
Update on funding
October 16, 2024
Update on funding and preliminary results
October 1, 2024
Progression of patient cohorts in PROTECT Trial
September 17, 2024
Trading update for the year ended 30 June 2024
July 22, 2024
Appointment of Nominated Adviser and Sole Broker
July 22, 2024
Launch of new Company Long Term Incentive Plan
July 4, 2024
Appointment of Non-Executive Director
June 27, 2024
Successful meetings with Paul Ehrlich Institut
June 3, 2024
Further detail from G306 Phase III field trial
May 7, 2024
Director Resignation
April 3, 2024
Interim Results for six months ended 31 Dec 2023
March 27, 2024
VLP Peanut PROTECT Trial Update
March 12, 2024
Appointment of Shaun Furlong to Board of Directors
March 11, 2024
Result of AGM
March 8, 2024
Half-Year Trading Update 2024
February 14, 2024
Notice of 2023 Annual General Meeting
February 9, 2024
Allergy Therapeutics plc - Publication of Annual Report and Accounts 2023
January 31, 2024
Restoration - Allergy Therapeutics plc
January 30, 2024
Publication of Annual Report and Accounts 2023
January 30, 2024
Total Voting Rights
January 4, 2024
Suspension - Allergy Therapeutics plc
January 2, 2024